Publications, Pharmaceutical

Evaluation of Albuterol Sulfate with Low Global Warming Potential Propellants

Reformulating widely used inhaled medications with propellants with a lower global warming potential is an important strategy for improving the sustainability of respiratory therapies.

This paper presents experimental data for a reformulated propellant-only formulation of albuterol sulfate in HFA-152a, a relatively low global warming potential propellant. Aerodynamic particle size distribution data were generated and used to predict regional deposition of the albuterol sulfate. Drug absorption was predicted using a pharmacokinetic model. The results demonstrate the feasibility of producing a stable pressurized metered dose inhaler formulation of albuterol sulfate using HFA-152a. Central deposition behavior was observed to be comparable to a current commercial product (Ventolin).

Download Publication
15 May 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

24 Apr 2023

Navigating pMDI Reformulation 2.0

Publications, Pharmaceutical, Sustainability, Device Innovations, Market Insights, Product Solutions

Read More
19 Apr 2023

Developing More Sustainable pMDIs: A Q&A on Motivation, Progress and Challenges

Publications, Pharmaceutical, Product Solutions, Sustainability, Brand Differentiation, Market Insights

Read More
13 Mar 2023

Moving Towards Greater Recyclability in Drug Delivery – Sustainable Solutions b...

Webinars, Pharmaceutical, Sustainability, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
13 Mar 2023

Orbital™ – A Novel Dry Powder Inhaler for High Dose Delivery

Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations

Read More
1 2 3 4 17
Back To Top